Eplontersen NDA submitted to FDA; tofersen under regulatory review for marketing approval in U.S. and EU Phase 3 data planned for eplontersen and olezarsen; robust late-stage pipeline expanding with two new Phase 3 programs Ionis provides full year 2023 financial guidance CARLSBAD, Calif. , Feb.
Ionis announces new donidalorsen data and presentations at the 2023 American Academy of Allergy, Asthma & Immunology Annual Meeting
Phase 2 open-label study data reinforce donidalorsen’s potential to be a best-in-class prophylactic treatment for patients living with hereditary angioedema Ionis is preparing to launch donidalorsen, one of its three near-term commercial opportunities CARLSBAD, Calif. , Feb.
Ionis to hold fourth quarter and full year 2022 financial results webcast
Webcast scheduled for Wednesday, February 22 at 11:30 a.m. Eastern Time CARLSBAD, Calif. , Feb. 8, 2023 /PRNewswire/ — Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that it will host a live webcast on Wednesday, February 22 nd at 11:30 a.m.
Ionis announces GSK has advanced bepirovirsen into Phase 3 development
Initiation of the Phase 3 program expands Ionis’ late-stage pipeline to 7 medicines in 9 indications CARLSBAD, Calif. , Feb. 1, 2023 /PRNewswire/ — Ionis Pharmaceuticals, Inc. ( Nasdaq : IONS) today announced that GSK has initiated two randomized, double-blind, placebo-controlled Phase 3 studies
Ionis receives FDA Fast Track designation for olezarsen in patients with familial chylomicronemia syndrome
FCS is a rare and debilitating genetic disease often leading to significant risk of acute, potentially fatal pancreatitis If approved, olezarsen would be the first approved treatment for FCS in the U.S. CARLSBAD, Calif. , Jan. 31, 2023 /PRNewswire/ — Ionis Pharmaceuticals, Inc.